Stella Diagnostics to Present Data on Discovery of Proteomic Chemoresistance Network in Esophageal Cancer Tissue

Rhea-AI Summary

Stella Diagnostics, Inc (OTC PINK:JMDP) announced that CEO Dr. Joe Abdo will present at the 32^nd EORTC NCI AACR Symposium on October 24-25, 2020. The presentation focuses on research regarding esophageal adenocarcinoma, the fastest rising cancer in the U.S., with a 600% increase in incidence over 25 years. Dr. Abdo's study identifies biomarkers linked to resistance against common chemotherapies, highlighting a need for new diagnostic and treatment options for patients. The presentation will be available on demand through the conference website.

NEW YORK, NY / ACCESSWIRE / October 22, 2020 / Stella Diagnostics, Inc. (OTC PINK:JMDP), a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease, today announced that Chief Executive Officer, Dr. Joe Abdo will deliver a company presentation (Abstract ID 148) at the 32^nd EORTC NCI AACR Symposium on Molecular Targets and Cancer Therapeutics, being held virtually October 24-25, 2020. The data presentation is entitled "Discovery Proteomics Detects Expression Trends Associated with Resistance to the Most Commonly Used Chemotherapies in Esophageal Adenocarcinoma (EAC)" and was accepted after peer-review in the Drug Resistance and Modifiers session.

"Esophageal adenocarcinoma is the deadliest form of cancer relative to incidence in the United States and is also one of the least researched neoplasms despite its increasing prevalence. Strikingly, esophageal adenocarcinoma is the fastest rising cancer in the U.S. with a 600% increase over the past 25 years," explained first author of the abstract, Dr. Sumeet Mittal.

Dr. Mittal is a board-certified general surgeon and Surgical Director of the Esophageal and Foregut Program at Norton Thoracic Institute, St. Joseph's Hospital and Medical Center. Dr. Mittal is a Clinical Advisor for the Company.

"Our group was intrigued by esophageal cancer's ability to consistently resist combination chemotherapeutics and evade sensitization to drugs like cisplatin, taxanes and anthracyclines," said Dr. Abdo. "Therefore, we designed a molecular dragnet to detect and quantify expression trends in esophageal cancer cells that are associated with chemoresistance. We discovered a network of consistently down-regulated or overexpressed biomarkers that may contribute to broad resistance against common chemotherapies currently used for first-line therapy for EAC."

Dr. Mittal added, "Ultimately, these findings demonstrate a clinical need for actionable molecular diagnostics and new targeted therapy options for EAC patients."

The Company's presentation will be available on demand to registered participants through the conference website.

About Stella Diagnostics

Stella Diagnostics, Inc. is a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease. StellaDX's clinical assay will offer physicians insight into the molecular properties of their patients' tissue to determine if the disease is stable, progressing or turning cancerous. Using targeted mass spectrometry proteomics, we believe that informing physicians of the expression patterns playing a role in the pathogenesis of GERD, Barrett's esophagus and esophageal cancer early in the treatment plan may extend or save lives. For more information, please visit (www.stelladx.com).

STELLA DIAGNOSTICS CONTACTS:

Investors and Media Contact:

Stella Diagnostics, Inc.
Email: info@stelldx.com
Phone: 201-381-1474

SOURCE: Stella Diagnostics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/611798/Stella-Diagnostics-to-Present-Data-on-Discovery-of-Proteomic-Chemoresistance-Network-in-Esophageal-Cancer-Tissue

FAQ

What is the focus of Stella Diagnostics' presentation at the EORTC NCI AACR Symposium?

The presentation focuses on the discovery of biomarkers associated with chemoresistance in esophageal adenocarcinoma.

When will Stella Diagnostics present at the EORTC NCI AACR Symposium?

Stella Diagnostics will present on October 24-25, 2020.

What is the significance of esophageal adenocarcinoma according to Stella Diagnostics?

Esophageal adenocarcinoma is the fastest rising cancer in the U.S., with a 600% increase in incidence over the last 25 years.

Where can I find Stella Diagnostics' presentation?

The presentation will be available on demand to registered participants through the conference website.

What is the ticker symbol for Stella Diagnostics?

The ticker symbol for Stella Diagnostics is JMDP.